Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients admitted for elective cardiac surgery under cardiopulmonary bypass, with no exclusion criteria, and having signed an informed consent, will be enrolled in the study.~Exclusion Criteria:~* Patients \< 18 years~* Urgent surgery~* Off-pump cardiac surgery~* Redo cardiac surgery~* Preoperative anemia (Hb \< 10g/l or Ht \< 30%)~* Transfusion within 72h preoperatively~* Pregnancy~* History of asthma or other specific allergies~* History of allergy to iron~* Acute infection~* Hepatic insufficiency~* Renal insufficiency (creatinine Clearance \< 30ml/min)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose group (Type: ACTIVE_COMPARATOR): Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).